Type II monocytes modulate T cell–mediated central nervous system autoimmune diseaseMartin S. Weber, Scott S. Zamvil, Juan C. Patarroyo et al.|Nature Medicine|2007Cited by 448
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Sana Syed et al.|New England Journal of Medicine|2019Cited by 320
BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repairAnastasia Geladaris, Martin S. Weber|Acta Neuropathologica|2024Cited by 39
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuß, Amit Bar‐Or, Robert A Bermel et al.|Therapeutic Advances in Neurological Disorders|2024Cited by 23